Clinical Trial Update: This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment [Phase 2]

View source ↗

Summary

A prospective, one-arm Phase II trial evaluating apatinib in combination with albumin-bound paclitaxel and carboplatin for neoadjuvant therapy in triple-negativ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Apatinib (apatinib)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer | Phase 2 | Status: UNKNOWN